Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Interventional Phase IV Study to Assess the Safety of EupentaTM Inj. {Fully Liquid Pentavalent Vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [Recombinant-deoxyribonucleic Acid])-Haemophilus Influenzae Type b Conjugate Vaccine}

NCT04056728 is registered in ClinicalTrials.gov with LG Chem as lead sponsor.

NCT NCT04056728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04056728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Interventional Phase IV Study to Assess the Safety of EupentaTM Inj. {Fully Liquid Pentavalent Vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [Recombinant-deoxyribonucleic Acid])-Haemophilus Influenzae Type b Conjugate Vaccine}
Lead sponsor
LG Chem
Phase
Phase 4
Overall status
Unknown status
Start date
September 23, 2019
Completion date
December 31, 2020
Enrollment
3,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, haemophilus influenzae type b infection, hepatitis b, pertussis, tetanus